JP2024056778A5 - - Google Patents

Download PDF

Info

Publication number
JP2024056778A5
JP2024056778A5 JP2024015750A JP2024015750A JP2024056778A5 JP 2024056778 A5 JP2024056778 A5 JP 2024056778A5 JP 2024015750 A JP2024015750 A JP 2024015750A JP 2024015750 A JP2024015750 A JP 2024015750A JP 2024056778 A5 JP2024056778 A5 JP 2024056778A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
target protein
antisense oligomer
produced
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024015750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024056778A (ja
JP7783920B2 (ja
Filing date
Publication date
Priority claimed from JP2020522905A external-priority patent/JP7475272B2/ja
Application filed filed Critical
Publication of JP2024056778A publication Critical patent/JP2024056778A/ja
Publication of JP2024056778A5 publication Critical patent/JP2024056778A5/ja
Application granted granted Critical
Publication of JP7783920B2 publication Critical patent/JP7783920B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024015750A 2017-10-23 2024-02-05 ナンセンス変異依存ｒｎａ分解機構に基づく状態および疾患の処置のためのアンチセンスオリゴマー Active JP7783920B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762575924P 2017-10-23 2017-10-23
US62/575,924 2017-10-23
US201862667200P 2018-05-04 2018-05-04
US62/667,200 2018-05-04
JP2020522905A JP7475272B2 (ja) 2017-10-23 2018-10-23 ナンセンス変異依存ｒｎａ分解機構に基づく状態および疾患の処置のためのアンチセンスオリゴマー
PCT/US2018/057165 WO2019084050A1 (en) 2017-10-23 2018-10-23 ANTISENSE OLIGOMERS FOR THE TREATMENT OF CONDITIONS AND DISEASES BASED ON THE DECLINE OF NON-SENSE MEDIATED MRNA

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020522905A Division JP7475272B2 (ja) 2017-10-23 2018-10-23 ナンセンス変異依存ｒｎａ分解機構に基づく状態および疾患の処置のためのアンチセンスオリゴマー

Publications (3)

Publication Number Publication Date
JP2024056778A JP2024056778A (ja) 2024-04-23
JP2024056778A5 true JP2024056778A5 (enExample) 2024-11-07
JP7783920B2 JP7783920B2 (ja) 2025-12-10

Family

ID=66247689

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020522905A Active JP7475272B2 (ja) 2017-10-23 2018-10-23 ナンセンス変異依存ｒｎａ分解機構に基づく状態および疾患の処置のためのアンチセンスオリゴマー
JP2024015750A Active JP7783920B2 (ja) 2017-10-23 2024-02-05 ナンセンス変異依存ｒｎａ分解機構に基づく状態および疾患の処置のためのアンチセンスオリゴマー

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020522905A Active JP7475272B2 (ja) 2017-10-23 2018-10-23 ナンセンス変異依存ｒｎａ分解機構に基づく状態および疾患の処置のためのアンチセンスオリゴマー

Country Status (23)

Country Link
US (2) US20210268667A1 (enExample)
EP (2) EP3700570B1 (enExample)
JP (2) JP7475272B2 (enExample)
KR (2) KR20250025519A (enExample)
CN (2) CN120290560A (enExample)
AU (1) AU2018355237B2 (enExample)
BR (1) BR112020007881A2 (enExample)
CA (1) CA3079729A1 (enExample)
DK (1) DK3700570T3 (enExample)
ES (1) ES3015767T3 (enExample)
FI (1) FI3700570T3 (enExample)
GB (2) GB2584204B (enExample)
HR (1) HRP20250322T1 (enExample)
HU (1) HUE070436T2 (enExample)
IL (1) IL274023A (enExample)
LT (1) LT3700570T (enExample)
PL (1) PL3700570T3 (enExample)
PT (1) PT3700570T (enExample)
RS (1) RS66633B1 (enExample)
SG (1) SG11202003692YA (enExample)
SI (1) SI3700570T1 (enExample)
SM (1) SMT202500127T1 (enExample)
WO (1) WO2019084050A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
WO2016040748A1 (en) 2014-09-12 2016-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for detection of smn protein in a subject and treatment of a subject
CA2963288A1 (en) 2014-10-03 2016-04-07 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
WO2016130600A2 (en) 2015-02-09 2016-08-18 Duke University Compositions and methods for epigenome editing
AU2016334804B2 (en) 2015-10-09 2022-03-31 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
WO2017066497A2 (en) 2015-10-13 2017-04-20 Duke University Genome engineering with type i crispr systems in eukaryotic cells
EP3384055B1 (en) 2015-11-30 2025-07-16 Duke University Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2017106377A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
EP3471779A4 (en) 2016-06-16 2020-07-08 Ionis Pharmaceuticals, Inc. COMBINATIONS FOR MODULATING SMN EXPRESSION
EP3487523B1 (en) 2016-07-19 2023-09-06 Duke University Therapeutic applications of cpf1-based genome editing
LT3673080T (lt) 2017-08-25 2023-12-27 Stoke Therapeutics, Inc. Priešprasminiai oligomerai, skirti būklėms ir ligoms gydyti
BR112020022512A2 (pt) 2018-05-04 2021-05-04 Stoke Therapeutics, Inc. métodos e composições para tratamento de doença de armazenamento de éster de colesteril
CN109593771B (zh) * 2018-07-27 2022-03-29 四川大学华西医院 一种人类map2k5第1100位碱基突变基因及其检测试剂盒
EP3942049A4 (en) 2019-03-20 2023-10-18 President And Fellows Of Harvard College ANTISENSE OLIGONUCLEOTIDE BASED PROGRANULIN AUGMENTATION THERAPY FOR NEURODEGENERATIVE DISEASES
CN113728104B (zh) 2019-03-29 2023-10-27 Ionis制药公司 用于调节ube3a-ats的化合物和方法
JP2022544702A (ja) * 2019-08-19 2022-10-20 ストーク セラピューティクス，インク． スプライシングおよびタンパク質発現を調節するための組成物および方法
US11618900B2 (en) * 2019-11-01 2023-04-04 The Johns Hopkins University Modulating SYNGAP
AU2020395835A1 (en) * 2019-12-06 2022-06-23 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases
CA3173034A1 (en) * 2020-02-28 2021-09-02 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating smn2
US20230124616A1 (en) * 2020-03-06 2023-04-20 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating kcnq2
US20230201375A1 (en) * 2020-04-27 2023-06-29 Duke University Targeted genomic integration to restore neurofibromin coding sequence in neurofibromatosis type 1 (nf1)
CN115916977A (zh) * 2020-05-11 2023-04-04 弗洛里神经科学与心理健康研究所 用于治疗与syngap1中功能失去突变相关的障碍的组合物和方法
EP4150092A4 (en) * 2020-05-11 2024-11-06 Stoke Therapeutics, Inc. OPA1 ANTISENSE OLIGOMERS FOR THE TREATMENT OF DISEASES AND CONDITIONS
CA3186629A1 (en) * 2020-07-22 2022-01-27 The Florey Institute Of Neuroscience And Mental Health Compositions and methods for treating disorders associated with loss-of-function mutations in scn2a
CA3186935A1 (en) 2020-08-07 2022-02-10 Paymaan JAFAR-NEJAD Compounds and methods for modulating scn2a
JP2023543494A (ja) * 2020-10-02 2023-10-16 ピーワイシー セラピューティクス リミテッド 視神経萎縮症の治療
WO2022093835A1 (en) * 2020-10-26 2022-05-05 Remix Therapeutics Inc. Oligonucleotides useful for modulation of splicing
AU2022215577A1 (en) * 2021-02-03 2023-09-21 Stoke Therapeutics, Inc. Compositions for treatment of conditions and diseases associated with polycystin expression
WO2022240795A1 (en) * 2021-05-10 2022-11-17 Q-State Biosciences, Inc. Compositions targeting sodium channel 1.6
CA3219628A1 (en) * 2021-05-28 2022-12-01 Beam Therapeutics Inc. Compositions and methods for the self-inactivation of base editors
WO2022271699A2 (en) * 2021-06-21 2022-12-29 Stoke Therapeutics, Inc. Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases
CN113584082B (zh) * 2021-06-22 2023-07-25 复旦大学附属眼耳鼻喉科医院 CRISPR/Cas9基因编辑系统及其在制备治疗遗传性感音神经性聋的药物中的应用
CN113584038B (zh) * 2021-09-09 2023-11-14 深圳雅济科技有限公司 一种治疗视网膜疾病的反义寡核苷酸组合及其应用
JP2024542950A (ja) * 2021-10-18 2024-11-19 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｃｄｋｌ５欠損症（ｃｄｄ）の治療において有用な組成物
WO2023086342A2 (en) * 2021-11-09 2023-05-19 Stoke Therapeutics, Inc. Opa1 antisense oligomers for treatment of conditions and diseases
CN114032323B (zh) * 2021-11-17 2023-08-08 云南省烟草农业科学研究院 一种与雪茄烟抗黑胫病基因紧密连锁的共显性ssr标记及其应用
WO2023102548A1 (en) * 2021-12-03 2023-06-08 Quralis Corporation Treatment of neurological diseases using modulators of kcnq2 gene transcripts
CN118765324A (zh) * 2022-01-31 2024-10-11 Pyc治疗有限公司 视神经萎缩的治疗方法
JP2025507683A (ja) * 2022-02-24 2025-03-21 キュー－ステート バイオサイエンシーズ， インコーポレイテッド Ｓｙｎｇａｐハプロ不全のための治療剤
CN116083427B (zh) * 2022-04-22 2025-10-03 齐齐哈尔大学 大豆高温诱导型启动子及其应用
CN115029347B (zh) * 2022-05-11 2024-02-20 珠海中科先进技术研究院有限公司 识别和调控肝肾细胞纤维化的分子监测序列、重组质粒、抑制病毒
EP4532723A2 (en) * 2022-06-01 2025-04-09 Stoke Therapeutics, Inc. Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases
CA3249584A1 (en) * 2022-06-07 2023-12-14 PYC Therapeutics Limited COMPOSITIONS AND METHODS OF TREATMENT OF A MONOGENIC NEURODEVELOPMENTAL DISORDER
US20250368991A1 (en) * 2022-06-28 2025-12-04 Agency For Science, Technology And Research Oligonucleotides
CN116735729B (zh) * 2023-01-07 2025-12-16 武汉瀚海新酶生物科技有限公司 mRNA、加帽酶活性检测试剂盒及检测系统和检测方法、应用
WO2024187106A2 (en) * 2023-03-09 2024-09-12 Leal Therapeutics, Inc. Compositions and methods for modulating grin2a
KR20240139000A (ko) * 2023-03-09 2024-09-20 고려대학교 산학협력단 L1td1 단백질을 포함하는 신경퇴행성 질환의 예방 또는 치료용 조성물
WO2024221049A1 (en) * 2023-04-28 2024-10-31 PYC Therapeutics Limited Agents and method of treatment for optic conditions
WO2024255792A1 (zh) * 2023-06-16 2024-12-19 舒泰神（北京）生物制药股份有限公司 一种人源MeCp2启动子及其用途
WO2025043278A1 (en) * 2023-08-25 2025-03-06 PYC Therapeutics Limited Gene-mediated conditions
WO2025091028A1 (en) * 2023-10-27 2025-05-01 The Regents Of The University Of Michigan Compounds and methods for modulating cln3 expression
CN117511947B (zh) * 2024-01-08 2024-03-29 艾斯拓康医药科技(北京)有限公司 一种优化的5`utr序列及其应用
CN117904327B (zh) * 2024-03-19 2024-07-30 浙江百迪生物科技有限公司 特异性检测人源基因的生物标志物、引物对、试剂盒及其应用
CN118421801B (zh) * 2024-07-03 2024-11-22 深圳市艾斯基因科技有限公司 结直肠癌高甲基化靶标及其应用
CN119060981B (zh) * 2024-09-04 2025-07-22 中国人民解放军军事科学院军事医学研究院 Perk蛋白突变体及其在预防uvb诱发皮肤光损伤反应中的应用
CN119552958A (zh) * 2024-11-29 2025-03-04 福州福瑞医学检验实验室有限公司 检测歌舞伎综合征kmt2d基因变异位点的多重荧光定量pcr引物、探针及试剂盒

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866042A (en) 1987-11-18 1989-09-12 Neuwelt Edward A Method for the delivery of genetic material across the blood brain barrier
US6294520B1 (en) 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
AU692423B2 (en) 1992-09-25 1998-06-11 Institut National De La Sante Et De La Recherche Medicale Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
US5656612A (en) 1994-05-31 1997-08-12 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
FR2727867B1 (fr) 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
US6187586B1 (en) 1999-12-29 2001-02-13 Isis Pharmaceuticals, Inc. Antisense modulation of AKT-3 expression
US6809194B1 (en) 2000-05-10 2004-10-26 Chiron Corporation Akt3 inhibitors
US20040078837A1 (en) * 2001-08-02 2004-04-22 Shannon Mark E. Four human zinc-finger-containing proteins: MDZ3, MDZ4, MDZ7 and MDZ12
US6936589B2 (en) 2001-09-28 2005-08-30 Albert T. Naito Parenteral delivery systems
AU2003225410A1 (en) * 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
US7374927B2 (en) * 2004-05-03 2008-05-20 Affymetrix, Inc. Methods of analysis of degraded nucleic acid samples
US8258109B2 (en) 2005-10-20 2012-09-04 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of LMNA expression
US8178503B2 (en) * 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
EP2170374A2 (en) * 2007-07-03 2010-04-07 Andreas Reichert Method for treating diseases related to mitochondrial dysfunction
CA2930393C (en) 2007-12-04 2022-11-29 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
EP2276855B1 (en) * 2008-03-13 2016-05-11 Celera Corporation Genetic polymorphisms associated wiith venous thrombosis, methods of detection and uses thereof
CA2735129C (en) * 2008-11-07 2012-06-26 Centre Hospitalier Universitaire Sainte-Justine Syngap1 dysfunctions and uses thereof in diagnostic and therapeutic applications for mental retardation
KR20200047790A (ko) 2009-06-17 2020-05-07 바이오젠 엠에이 인코포레이티드 대상에게서 ｓｍｎ２ 스플라이싱을 조정하기 위한 조성물 및 방법
EP3231446A1 (en) 2010-04-19 2017-10-18 Nlife Therapeutics S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
US20140128449A1 (en) 2011-04-07 2014-05-08 The Board Of Regents Of The University Of Texas System Oligonucleotide modulation of splicing
WO2013012758A1 (en) 2011-07-19 2013-01-24 Ontorii, Inc. Methods for the synthesis of functionalized nucleic acids
EA037123B1 (ru) 2012-02-10 2021-02-09 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии
BR112014028645A2 (pt) * 2012-05-16 2017-06-27 Rana Therapeutics Inc composições e métodos para modulação da expressão de apoa1 e abca1.
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
KR102314290B1 (ko) 2013-06-25 2021-10-21 에프. 호프만-라 로슈 아게 척수성 근위축증을 치료하기 위한 화합물
JP6689197B2 (ja) 2013-08-19 2020-04-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト スクリーニング方法
PL3041958T3 (pl) 2013-09-04 2020-11-02 Cold Spring Harbor Laboratory Redukcja rozpadu mRNA mediowanego sekwencjami nonsensownymi
US20180085391A1 (en) * 2014-08-08 2018-03-29 Modernatx, Inc. Compositions and methods for the treatment of ophthalmic diseases and conditions
JP6884102B2 (ja) 2015-02-09 2021-06-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための化合物
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
WO2017006382A1 (ja) 2015-07-03 2017-01-12 富士機械製造株式会社 供給交換装置及び印刷装置
JPWO2017006370A1 (ja) 2015-07-07 2018-04-19 オリンパス株式会社 デジタルホログラフィック撮影装置
EP3352872A4 (en) 2015-09-24 2019-07-10 The Trustees of the University of Pennsylvania TRIPTYENE DERIVATIVES FOR STABILIZING A NUCLEIC ACID COMPOUND
WO2017106382A1 (en) * 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Compositions and methods for treatment of central nervous system diseases
CA3005090A1 (en) * 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Compositions and methods for treatment of liver diseases
CA3005128A1 (en) * 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Compositions and methods for treatment of eye diseases
WO2017106377A1 (en) * 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome

Similar Documents

Publication Publication Date Title
JP2024056778A5 (enExample)
JP2022062140A5 (enExample)
JP2020189874A5 (enExample)
JP2024045199A5 (enExample)
GB2582457A (en) Antisense Oligomers for treatment of conditions and diseases
JP2017536338A5 (enExample)
JP2019500347A5 (enExample)
JP2021500041A5 (enExample)
KR102812602B1 (ko) Lpa 발현을 저해하기 위한 조성물 및 방법
FI3700570T3 (fi) Antisense-oligomeerejä nonsense-välitteiseen rna:n hajoamiseen pohjautuvien tilojen ja sairauksien hoitoon
AU2021236674B2 (en) Compositions and methods for inhibiting ANGPTL3 expression
JP2019501892A5 (enExample)
JP2019500346A5 (enExample)
JP2018538288A5 (enExample)
EP3044315B1 (en) Nucleic acids and methods for the treatment of pompe disease
JP2019500349A5 (enExample)
JP2018538287A5 (enExample)
JP2019500350A5 (enExample)
CA3173647A1 (en) Opa1 antisense oligomers for treatment of conditions and diseases
JP7756166B2 (ja) Ｒｎａ治療薬及びその使用方法
JP2022093334A (ja) アンチセンスオリゴヌクレオチドおよび糖原病Ｉａ型予防または治療用組成物
JP2024524974A (ja) ナンセンス変異依存ｒｎａ分解機構に基づく病態及び疾患の処置のためのアンチセンスオリゴマー
US11952574B2 (en) Compositions and methods for inhibiting transmembrane serine protease 6 (TMPRSS6) expression
JPWO2021231107A5 (enExample)
JP7725370B2 (ja) Ａｎｇｐｔｌ２アンチセンスオリゴヌクレオチドおよびその使用